Evercore ISI lowered the firm’s price target on Kenvue (KVUE) to $23 from $25 and keeps an In Line rating on the shares. The firm’s price target has been adjusted downward to reflect lower peer valuations and the premium Tylenol commands within Kenvue’s portfolio, but the analyst added that the recent selloff in shares “might be overdone” when considering the lack of a proven causal link between Tylenol’s active ingredient and neurodevelopmental disorders. Despite headline risks, a lack of definitive evidence linking acetaminophen to autism may suggest limited long-term impact, but legal uncertainties could delay strategic moves, the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Positive Buy Rating for Kenvue, Inc. Amid Favorable Legal and Regulatory Developments
- BofA sees ‘particularly attractive entry point’ after Kenvue pullback
- Kenvue, Inc. Hold Rating: Concerns Over Tylenol-Autism Link and Strategic Uncertainty
- Kenvue Stock (KVUE) Plunges on Report Linking Tylenol to Autism
- HHS says report of Tylenol, autism link ‘speculation,’ Bloomberg reports